Gilead Sciences, Inc. (GILD)
- Previous Close
67.08 - Open
66.59 - Bid 65.21 x 100
- Ask 65.31 x 600
- Day's Range
65.26 - 67.90 - 52 Week Range
65.26 - 87.87 - Volume
5,829,982 - Avg. Volume
7,193,293 - Market Cap (intraday)
81.402B - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
14.51 - EPS (TTM)
4.50 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 3.08 (4.59%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
83.88
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
www.gilead.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GILD
Performance Overview: GILD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GILD
Valuation Measures
Market Cap
83.65B
Enterprise Value
101.37B
Trailing P/E
14.91
Forward P/E
15.77
PEG Ratio (5yr expected)
0.69
Price/Sales (ttm)
3.11
Price/Book (mrq)
3.66
Enterprise Value/Revenue
3.74
Enterprise Value/EBITDA
9.66
Financial Highlights
Profitability and Income Statement
Profit Margin
20.89%
Return on Assets (ttm)
9.78%
Return on Equity (ttm)
25.54%
Revenue (ttm)
27.12B
Net Income Avi to Common (ttm)
5.66B
Diluted EPS (ttm)
4.50
Balance Sheet and Cash Flow
Total Cash (mrq)
8.35B
Total Debt/Equity (mrq)
112.79%
Levered Free Cash Flow (ttm)
8.79B
Research Analysis: GILD
Company Insights: GILD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GILD
Analyst Report: Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.
RatingPrice TargetMarket Digest: TSM, TFC, GILD, OMC, VZ
We've reported for weeks that the trading activity among corporate insiders in general, but on the tech-heavy Nasdaq in particular, was clearly suggesting that stocks likely had come too far, too fast. Further, insider-sentiment data from Vickers Stock Research left the clear impression that stocks were priced for perfection and vulnerable to events like inflation disappointment, geopolitical turmoil, or less-than-expected corporate earnings. Now, a mix of all those things seem to be in play and stocks are indeed experiencing rough sledding for the first time since about October. Reflecting the forecasting from Vickers, as of this writing the Nasdaq Composite and Nasdaq 100 have slid about 7% from the March 22 highs while the S&P 500 is off about 5%.
The Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But the tide turned in 2022. The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.
Weekly Stock List
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for more than a decade, the performance record favored growth. Since 2010, the Russell 1000 Growth Index has climbed more than 575%, compared to an advance of almost 200% for the Russell 1000 Value Index. In 10 of the past 13 years, growth stocks have topped value stocks. That hasn't always been the case. In the 2000-2010 decade, including the Great Recession, value stocks were better performers than growth stocks, advancing an admittedly low 8% (but still better than growth, which declined 15% during the decade). Value investors trace their roots to the famous "Security Analysis" textbook, written by Ben Graham, an economics professor at Columbia University. Warren Buffett was one of his students. Why the recent deviation in performance? Several reasons, including changes in the make-up of the economy, growth in intangible assets, and the current level of interest rates. But the tide turned back in 2022, at least for a while, as the rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent years. While growth stocks have recaptured the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income. The current yield on the iShares Russell 1000 Value Index ETF is 2.0%, compared to the 0.7% current yield on the iShares Russell 1000 Growth Index ETF. For our list this week, we have screened our coverage universe for stocks that are BUY-rated by Argus Research analysts, have an Argus Financial Strength Rating of at least Medium, and have a yield of 3.0% or higher. Here's a baker's dozen that meet the criteria. These stocks are also featured in our High-Yield theme model portfolio.